Trial Profile

A Phase 1 Clinical Study of CLY-124 for the Treatment of Sickle Cell Disease.

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 26 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CLY 124 (Primary)
Indications Sickle cell anaemia
Focus Adverse reactions; First in man

Most Recent Events

31 Oct 2025 According to cellarity media release,data from this trial will be presented at the 67th American Society of Hematology (ASH) Annual Meeting, December 6-9, 2025 in Orlando, Florida.
03 Jul 2025 New trial record
26 Jun 2025 According to cellarity media release, company announced successful clearance of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com